Gratus Capital’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $6.31M | Buy |
44,186
+12,518
| +40% | +$1.66M | 0.25% | 91 |
|
|
2024
Q1 | $4.07M | Hold |
31,668
| – | – | 0.19% | 98 |
|
|
2023
Q4 | $3.28M | Sell |
31,668
-150
| -0.5% | -$14.8K | 0.18% | 98 |
|
|
2023
Q3 | $2.89M | Hold |
31,818
| – | – | 0.2% | 90 |
|
|
2023
Q2 | $2.57M | Hold |
31,818
| – | – | 0.18% | 96 |
|
|
2023
Q1 | $2.53M | Sell |
31,818
-2,376
| -7% | -$168K | 0.19% | 84 |
|
|
2022
Q4 | $2.31M | Hold |
34,194
| – | – | 0.19% | 85 |
|
|
2022
Q3 | $1.7M | Sell |
34,194
-778
| -2% | -$41.7K | 0.18% | 94 |
|
|
2022
Q2 | $1.95M | Sell |
34,972
-450
| -1% | -$25K | 0.22% | 82 |
|
|
2022
Q1 | $1.97M | Sell |
35,422
-1,576
| -4% | -$80.9K | 0.19% | 86 |
|
|
2021
Q4 | $2.07M | Buy |
36,998
+656
| +2% | +$35.5K | 0.19% | 84 |
|
|
2021
Q3 | $1.75M | Buy |
36,342
+1,412
| +4% | +$68.3K | 0.19% | 84 |
|
|
2021
Q2 | $1.46M | Sell |
34,930
-16,190
| -32% | -$628K | 0.16% | 90 |
|
|
2021
Q1 | $1.72M | Sell |
51,120
-3,274
| -6% | -$117K | 0.21% | 98 |
|
|
2020
Q4 | $1.9M | Buy |
54,394
+114
| +0.2% | +$3.94K | 0.25% | 85 |
|
|
2020
Q3 | $1.88M | Sell |
54,280
-810
| -1% | -$27K | 0.29% | 80 |
|
|
2020
Q2 | $1.8M | Sell |
55,090
-1,262
| -2% | -$40.3K | 0.3% | 80 |
|
|
2020
Q1 | $1.7M | Sell |
56,352
-1,138
| -2% | -$33.9K | 0.32% | 82 |
|
|
2019
Q4 | $1.66M | Sell |
57,490
-2,250
| -4% | -$62.3K | 0.25% | 96 |
|
|
2019
Q3 | $1.54M | Sell |
59,740
-700
| -1% | -$17.7K | 0.25% | 99 |
|
|
2019
Q2 | $1.54M | Buy |
60,440
+1,160
| +2% | +$28.7K | 0.25% | 97 |
|
|
2019
Q1 | $1.55M | Buy |
59,280
+180
| +0.3% | +$4.42K | 0.26% | 95 |
|
|
2018
Q4 | $1.36M | Buy |
59,100
+200
| +0.3% | +$4.44K | 0.28% | 94 |
|
|
2018
Q3 | $1.39M | Sell |
58,900
-800
| -1% | -$19.5K | 0.19% | 91 |
|
|
2018
Q2 | $1.38M | Sell |
59,700
-2,300
| -4% | -$54.7K | 0.2% | 87 |
|
|
2018
Q1 | $1.53M | Hold |
62,000
| – | – | 0.22% | 88 |
|
|
2017
Q4 | $1.66M | Hold |
62,000
| – | – | 0.22% | 90 |
|
|
2017
Q3 | $1.49M | Hold |
62,000
| – | – | 0.21% | 91 |
|
|
2017
Q2 | $1.33M | Hold |
62,000
| – | – | 0.19% | 95 |
|
|
2017
Q1 | $1.06M | Buy |
62,000
+20,216
| +48% | +$352K | 0.15% | 103 |
|
|
2016
Q4 | $749K | Sell |
41,784
-1,272
| -3% | -$23.1K | 0.11% | 113 |
|
|
2016
Q3 | $895K | Buy |
43,056
+1,284
| +3% | +$31.8K | 0.13% | 111 |
|
|
2016
Q2 | $1.12M | Buy |
+41,772
| New | +$1.15M | 0.17% | 101 |
|
Other funds holding NVO
F
Gratus Capital's NVO Position: Q2 2024 in Review
Gratus Capital increased its Novo Nordisk (NVO) stake by 40% in Q2 2024, buying an estimated $1.66M and bringing the position to 44,186 shares worth $6.31M. The position accounts for 0.25% of the portfolio, ranked #91.
Gratus Capital first reported a position in NVO in Q2 2016 and has held it in 33 quarters since. 1,860 funds tracked by Wall St. Rank hold NVO as of Q2 2024.
- Gratus Capital held 44,186 shares of Novo Nordisk worth $6.31M as of Q2 2024.
- Gratus Capital bought 12,518 Novo Nordisk shares in Q2 2024, an estimated $1.66M.
- Novo Nordisk made up 0.25% of Gratus Capital's portfolio in Q2 2024, its #91 holding.
- Gratus Capital first reported a position in Novo Nordisk in Q2 2016 and has held it in 33 quarters since.
- 1,860 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.
Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.